Floatz logo

Mdna11

Unresectable Solid Tumor

Medicenna Therapeutics, Inc.Phase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

20 Active assets in the Unresectable Solid Tumor cohort.

Asset / SponsorPhaseRating
[177lu]lu-sn201
Spago Nanomedical AB
Phase 1/2CC
Pembrolizumab
Medicenna Therapeutics, Inc.
Phase 1/2CC
Fmc-376
Frontier Medicines Corporation
Phase 1/2CC
Rly-5836
Relay Therapeutics, Inc.
Phase 1CC
FULVESTRANT
Relay Therapeutics, Inc.
Phase 1CC

View all 20 →

Same molecule, other indications

Mdna11 is also rated in:

endometrial carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
basal cell carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
MSI-H Solid Malignant TumorDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →